Cervical cancer remains a major global health burden, particularly in advanced and recurrent disease, where therapeutic options are limited. We conducted a systematic review of clinical studies evaluating nab-paclitaxel-based regimens in cervical cancer, following PRISMA 2020 guidelines. Literature published between 2015 and 2025 was identified across five databases, and risk of bias was assessed using the MINORS tool. Ten studies (five single-arm and five comparative; n = 417) were included. Nab-paclitaxel was administered in combination with chemotherapy, radiotherapy, or immunotherapy. Across single-arm studies, objective response rates ranged from 40% to 57%, with median progression-free survival of 4.5-9.1 months and overall survival of 8.9-16.6 months. Comparative studies suggested higher response rates with nab-paclitaxel-cisplatin regimens, particularly in neoadjuvant settings. Nab-paclitaxel-based combinations demonstrated generally manageable toxicity. However, interpretation is limited by study heterogeneity and the absence of randomized controlled trials.
Wiwekananda et al. (2026) studied this question.